{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:51:39Z","timestamp":1767066699570,"version":"3.48.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["Grant No. ZR2024MH328, ZR2021QH079, ZR2019MH008, ZR2020MH238"],"award-info":[{"award-number":["Grant No. ZR2024MH328, ZR2021QH079, ZR2019MH008, ZR2020MH238"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2021CXGC011105"],"award-info":[{"award-number":["2021CXGC011105"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 81900728, 82072676,82172791,82203766"],"award-info":[{"award-number":["Grant No. 81900728, 82072676,82172791,82203766"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Medical and Health Technology Development Project","award":["Grant No. 2018WSB20002"],"award-info":[{"award-number":["Grant No. 2018WSB20002"]}]},{"name":"Clinical Research Foundation of Shandong University","award":["Grant No. 2020SDUCRCA018"],"award-info":[{"award-number":["Grant No. 2020SDUCRCA018"]}]},{"DOI":"10.13039\/100014103","name":"Key Research and Development Program of Shandong Province","doi-asserted-by":"crossref","award":["Grant No. 2019GSF108254"],"award-info":[{"award-number":["Grant No. 2019GSF108254"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cholangiocarcinoma (CCA) is an aggressive malignancy with limited therapeutic options. Increasing evidence suggests that a subset of CCA patients can benefit from multiple tyrosine kinase inhibitors (mTKIs) such as surufatinib. Biomarker studies that can identify potential responders to mTKI therapy are crucial for improving treatment outcomes. In this study, we examined the expression of protein tyrosine phosphatase non-receptor type 9 (PTPN9) in CCA patients treated with surufatinib and analyzed its association with treatment response. Immunoprecipitation coupled with mass spectrometry (IP-MS) was performed to identify novel PTPN9 substrates. Orthotopic mouse models, biochemical assays, structural analyses, and functional experiments were conducted to validate these novel findings. Single-cell RNA sequencing, ELISA, and immunohistochemistry were utilized to investigate microenvironmental tumor-promoting factors.<\/jats:p>\n                  <jats:p>CCA patients with surufatinib non-response exhibited significantly decreased PTPN9 expression compared to that response to surufatinib. PTPN9 knockdown in orthotopic models led to reduced sensitivity to surufatinib. IGF1R was identified as a new substrate of PTPN9, which preferably to dephosphorylate IGF1R at Y1166. In clinical tissues, PTPN9 expression was inversely correlated with IGF1R Y1165\/1166 phosphorylation. Establishment of a surufatinib-resistant CCA cell line further confirmed decreased PTPN9 expression and elevated IGF1R signaling. In vivo blockade of IGF1R signaling significantly enhanced surufatinib sensitivity. Mechanistically, crystal structure analysis revealed Tyr333 and Asp335 as key PTPN9 residues interacting with IGF1R; mutation of these residues restored IGF1R signaling and abolished the tumor-suppressive effect of PTPN9. Furthermore, cancer-associated fibroblasts (CAFs) were identified as the major source of IGF1 in CCA microenvironment, essential for IGF1R-driven tumor progression.<\/jats:p>\n                  <jats:p>In summary, the PTPN9\u2013IGF1R axis plays a pivotal role in modulating mTKI sensitivity and tumor progression in CCA. This axis serves as a promising biomarker for identifying potential mTKI beneficiaries and represents a potential therapeutic target to enhance mTKI efficacy and overcome resistance.<\/jats:p>","DOI":"10.1186\/s13046-025-03594-2","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T13:04:35Z","timestamp":1763816675000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PTPN9 dephosphorylates IGF1RY1165\/1166 and alleviates IGF1R-mediated resistance to tyrosine kinase inhibitor in cholangiocarcinoma"],"prefix":"10.1186","volume":"44","author":[{"given":"Jia-ming","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-qiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian-li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An-da","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-fei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang-shuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zong-li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"3594_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7:65.","journal-title":"Nat Rev Dis Primers"},{"key":"3594_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3594_CR3","doi-asserted-by":"crossref","unstructured":"Speckart J, Rasmusen V, Talib Z, GnanaDev DA, Rahnemai-Azar AA. Emerging therapies in management of cholangiocarcinoma. Cancers (Basel) 2024;16(3):613..","DOI":"10.3390\/cancers16030613"},{"key":"3594_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104\u201314.","journal-title":"J Hepatol"},{"key":"3594_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.ajpath.2024.11.005","volume":"195","author":"H Ellis","year":"2025","unstructured":"Ellis H, Braconi C, Valle JW, Bardeesy N. Cholangiocarcinoma targeted therapies: mechanisms of action and resistance. Am J Pathol. 2025;195:437\u201352.","journal-title":"Am J Pathol"},{"key":"3594_CR6","doi-asserted-by":"publisher","first-page":"1435639","DOI":"10.3389\/fphar.2024.1435639","volume":"15","author":"KS Li","year":"2024","unstructured":"Li KS, Liu Y, Zhang TZ, Xu YF, Zhang ZL. Protocol of REACH-01: a single-arm, open label, prospective study of HAIC sequential TAE combined with Tislelizumab and Surufatinib in unresectable intrahepatic cholangiocarcinoma. Front Pharmacol. 2024;15:1435639.","journal-title":"Front Pharmacol"},{"key":"3594_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2024.42.3_suppl.486","volume":"42","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Ma C, Li E, Gao Y, Bao G, Lu J, et al. Efficacy and safety of surufatinib in biliary tract cancer: preliminary results of a real-world study. J Clin Oncol. 2024;42:486\u2013486.","journal-title":"J Clin Oncol"},{"key":"3594_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1483","volume":"13","author":"M Zhou","year":"2024","unstructured":"Zhou M, Jin Y, Zhu S, Xu C, Li L, Liu B, et al. A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer. Clinical & Translational Immunology. 2024;13:e1483.","journal-title":"Clinical & Translational Immunology"},{"key":"3594_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"GM Shi","year":"2023","unstructured":"Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, et al. Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduction and Targeted Therapy. 2023;8:106.","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"3594_CR10","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1200\/JCO.2025.43.16_suppl.4087","volume":"43","author":"K Li","year":"2025","unstructured":"Li K, Zhang T, Gao Q, Wang D, Liu Y, Chen H, et al. HAIC plus TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma: the REACH-01 trial. J Clin Oncol. 2025;43:4087\u20134087.","journal-title":"J Clin Oncol"},{"key":"3594_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44795-1","volume":"15","author":"JC Lu","year":"2024","unstructured":"Lu JC, Wu LL, Sun YN, Huang XY, Gao C, Guo XJ, et al. Macro CD5L(+) deteriorates CD8(+)T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma. Nat Commun. 2024;15:621.","journal-title":"Nat Commun"},{"key":"3594_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2025.2574526","volume":"57","author":"J Wang","year":"2025","unstructured":"Wang J, Wang J, Chen J. Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer. Ann Med. 2025;57:2574526.","journal-title":"Ann Med"},{"key":"3594_CR13","doi-asserted-by":"crossref","unstructured":"Gomatou G, Syrigos N, Kotteas E. Osimertinib resistance: molecular mechanisms and emerging treatment options. Cancers (Basel). 2023;15(3):841.","DOI":"10.3390\/cancers15030841"},{"key":"3594_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202405083","volume":"12","author":"S Huang","year":"2025","unstructured":"Huang S, Qin X, Fu S, Hu J, Jiang Z, Hu M, et al. STAMBPL1\/TRIM21 balances AXL stability impacting mesenchymal phenotype and immune response in KIRC. Adv Sci. 2025;12:e2405083.","journal-title":"Adv Sci"},{"key":"3594_CR15","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1038\/s41388-024-03126-w","volume":"43","author":"S Huang","year":"2024","unstructured":"Huang S, Hu J, Hu M, Hou Y, Zhang B, Liu J, et al. Cooperation between SIX1 and DHX9 transcriptionally regulates integrin-focal adhesion signaling mediated metastasis and sunitinib resistance in KIRC. Oncogene. 2024;43:2951\u201369.","journal-title":"Oncogene"},{"key":"3594_CR16","doi-asserted-by":"publisher","first-page":"1408852","DOI":"10.3389\/fcell.2024.1408852","volume":"12","author":"J Wang","year":"2024","unstructured":"Wang J, Liu S, Cao Y, Chen Y. Overcoming treatment resistance in cholangiocarcinoma: current strategies, challenges, and prospects. Front Cell Dev Biol. 2024;12:1408852.","journal-title":"Front Cell Dev Biol"},{"key":"3594_CR17","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin H, Shi Y, Lv Y, Yuan S, Ramirez CFA, Lieftink C, Wang L, et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature. 2021;595:730\u20134.","journal-title":"Nature"},{"key":"3594_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/0008-5472.CAN-22-0963","volume":"83","author":"M Huang","year":"2023","unstructured":"Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, et al. METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. Cancer Res. 2023;83:89\u2013102.","journal-title":"Cancer Res"},{"key":"3594_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01998-w","volume":"23","author":"YF Tang","year":"2024","unstructured":"Tang YF, Liu ZH, Zhang LY, Shi SH, Xu S, Ma JA, et al. circ_PPAPDC1A promotes Osimertinib resistance by sponging the miR-30a-3p\/ IGF1R pathway in non-small cell lung cancer (NSCLC). Mol Cancer. 2024;23:91.","journal-title":"Mol Cancer"},{"key":"3594_CR20","doi-asserted-by":"crossref","unstructured":"Song D, Wu Y, Li J, Liu J, Yi Z, Wang X, Sun J et al. Insulin-like growth factor 2 drives fibroblast-mediated tumor immunoevasion and confers resistance to immunotherapy. J Clin Invest 2024;134(22):e183366.","DOI":"10.1172\/JCI183366"},{"key":"3594_CR21","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1158\/0008-5472.CAN-18-2762","volume":"79","author":"L Benito-Jard\u00f3n","year":"2019","unstructured":"Benito-Jard\u00f3n L, D\u00edaz-Mart\u00ednez M, Arellano-S\u00e1nchez N, Vaquero-Morales P, Espar\u00eds-Ogando A, Teixid\u00f3 J. Resistance to MAPK inhibitors in melanoma involves activation of the IGF1R-MEK5-Erk5 pathway. Cancer Res. 2019;79:2244\u201356.","journal-title":"Cancer Res"},{"key":"3594_CR22","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1158\/1541-7786.MCR-19-0956","volume":"18","author":"T Manabe","year":"2020","unstructured":"Manabe T, Yasuda H, Terai H, Kagiwada H, Hamamoto J, Ebisudani T, et al. IGF2 autocrine-mediated IGF1R activation is a clinically relevant mechanism of Osimertinib resistance in lung cancer. Mol Cancer Res. 2020;18:549\u201359.","journal-title":"Mol Cancer Res"},{"key":"3594_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12943-016-0576-5","volume":"16","author":"H Li","year":"2017","unstructured":"Li H, Batth IS, Qu X, Xu L, Song N, Wang R, Liu Y. IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights. Mol Cancer. 2017;16:6.","journal-title":"Mol Cancer"},{"key":"3594_CR24","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1038\/s41388-023-02849-6","volume":"42","author":"W Jiang","year":"2023","unstructured":"Jiang W, Yang X, Shi K, Zhang Y, Shi X, Wang J, Wang Y, et al. MAD2 activates IGF1R\/PI3K\/AKT pathway and promotes cholangiocarcinoma progression by interfering USP44\/LIMA1 complex. Oncogene. 2023;42:3344\u201357.","journal-title":"Oncogene"},{"key":"3594_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167521","volume":"1871","author":"C Rattanasinchai","year":"2025","unstructured":"Rattanasinchai C, Navasumrit P, Chornkrathok C, Ruchirawat M. Kinase library screening identifies IGF-1R as an oncogenic vulnerability in intrahepatic cholangiocarcinoma stem-like cells. Biochimica et Biophysica Acta (BBA). 2025;1871:167521.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"3594_CR26","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/s41419-018-1025-8","volume":"9","author":"J Zorea","year":"2018","unstructured":"Zorea J, Prasad M, Cohen L, Li N, Schefzik R, Ghosh S, Rotblat B, et al. IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer. Cell Death Dis. 2018;9:944.","journal-title":"Cell Death Dis"},{"key":"3594_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109583","volume":"121","author":"R Sun","year":"2020","unstructured":"Sun R, Chen T, Li M, Liu Z, Qiu B, Li Z, et al. PTPN3 suppresses the proliferation and correlates with favorable prognosis of perihilar cholangiocarcinoma by inhibiting AKT phosphorylation. Biomed Pharmacother. 2020;121:109583.","journal-title":"Biomed Pharmacother"},{"key":"3594_CR28","doi-asserted-by":"publisher","first-page":"835914","DOI":"10.3389\/fpubh.2022.835914","volume":"10","author":"M Lertpanprom","year":"2022","unstructured":"Lertpanprom M, Silsirivanit A, Tippayawat P, Proungvitaya T, Roytrakul S, Proungvitaya S. High expression of protein tyrosine phosphatase receptor S (PTPRS) is an independent prognostic marker for cholangiocarcinoma. Front Public Health. 2022;10:835914.","journal-title":"Front Public Health"},{"key":"3594_CR29","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/1541-7786.MCR-20-0165","volume":"18","author":"EH Buckarma","year":"2020","unstructured":"Buckarma EH, Werneburg NW, Conboy CB, Kabashima A, O\u2019Brien DR, Wang C, et al. The YAP-interacting phosphatase SHP2 can regulate transcriptional coactivity and modulate sensitivity to chemotherapy in cholangiocarcinoma. Mol Cancer Res. 2020;18:1574\u201388.","journal-title":"Mol Cancer Res"},{"key":"3594_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1097\/HEP.0000000000000552","volume":"79","author":"L Zhao","year":"2024","unstructured":"Zhao L, Liu J, Li K, Zhang C, Chen T, Liu Z, Tang Y, et al. PTPN9 dephosphorylates FGFR2 pY656\/657 through interaction with ACAP1 and ameliorates Pemigatinib effect in cholangiocarcinoma. Hepatology. 2024;79:798\u2013812.","journal-title":"Hepatology"},{"key":"3594_CR31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-020-00904-3","volume":"13","author":"H Hua","year":"2020","unstructured":"Hua H, Kong Q, Yin J, Zhang J, Jiang Y. Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy. J Hematol Oncol. 2020;13:64.","journal-title":"J Hematol Oncol"},{"key":"3594_CR32","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","volume":"39","author":"S Affo","year":"2021","unstructured":"Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, et al. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;39:866\u2013e882811.","journal-title":"Cancer Cell"},{"key":"3594_CR33","first-page":"957","volume":"21","author":"C Chuaysri","year":"2009","unstructured":"Chuaysri C, Thuwajit P, Paupairoj A, Chau-In S, Suthiphongchai T, Thuwajit C. Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol Rep. 2009;21:957\u201369.","journal-title":"Oncol Rep"},{"key":"3594_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-025-01688-0","volume":"18","author":"H Jia","year":"2025","unstructured":"Jia H, Chen X, Zhang L, Chen M. Cancer associated fibroblasts in cancer development and therapy. J Hematol Oncol. 2025;18:36.","journal-title":"J Hematol Oncol"},{"key":"3594_CR35","doi-asserted-by":"publisher","first-page":"24923","DOI":"10.1074\/jbc.M113.482737","volume":"288","author":"G Fan","year":"2013","unstructured":"Fan G, Lin G, Lucito R, Tonks NK. Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK\/PTK6 in ovarian cancer cells. J Biol Chem. 2013;288:24923\u201334.","journal-title":"J Biol Chem"},{"key":"3594_CR36","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","volume":"8","author":"C Fedele","year":"2018","unstructured":"Fedele C, Ran H, Diskin B, Wei W, Jen J, Geer MJ, et al. SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models. Cancer Discov. 2018;8:1237\u201349.","journal-title":"Cancer Discov"},{"key":"3594_CR37","doi-asserted-by":"publisher","first-page":"7275","DOI":"10.1073\/pnas.0710468105","volume":"105","author":"K Hellmuth","year":"2008","unstructured":"Hellmuth K, Grosskopf S, Lum CT, W\u00fcrtele M, R\u00f6der N, von Kries JP, et al. Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking. Proc Natl Acad Sci U S A. 2008;105:7275\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3594_CR38","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2147\/CMAR.S187001","volume":"11","author":"D Wang","year":"2019","unstructured":"Wang D, Cheng Z, Zhao M, Jiao C, Meng Q, Pan H, Xie Y, et al. PTPN9 induces cell apoptosis by mitigating the activation of Stat3 and acts as a tumor suppressor in colorectal cancer. Cancer Manag Res. 2019;11:1309\u201319.","journal-title":"Cancer Manag Res"},{"key":"3594_CR39","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s40265-021-01489-y","volume":"81","author":"YY Syed","year":"2021","unstructured":"Syed YY. Surufatinib: first approval. Drugs. 2021;81:727\u201332.","journal-title":"Drugs"},{"key":"3594_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s42004-023-01084-0","volume":"7","author":"Q Lin","year":"2024","unstructured":"Lin Q, Dai S, Qu L, Lin H, Guo M, Wei H, Chen Y, et al. Structural basis and selectivity of Sulfatinib binding to FGFR and CSF-1R. Commun Chem. 2024;7:3.","journal-title":"Commun Chem"},{"key":"3594_CR41","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","volume":"21","author":"J Xu","year":"2020","unstructured":"Xu J, Shen L, Zhou Z, Li J, Bai C, Chi Y, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:1500\u201312.","journal-title":"Lancet Oncol"},{"key":"3594_CR42","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1158\/1078-0432.CCR-17-3725","volume":"24","author":"J Vaquero","year":"2018","unstructured":"Vaquero J, Lobe C, Tahraoui S, Clap\u00e9ron A, Mergey M, Merabtene F, et al. The IGF2\/IR\/IGF1R pathway in tumor cells and myofibroblasts mediates resistance to EGFR inhibition in cholangiocarcinoma. Clin Cancer Res. 2018;24:4282\u201396.","journal-title":"Clin Cancer Res"},{"key":"3594_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102170","volume":"95","author":"L Goyal","year":"2021","unstructured":"Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021;95:102170.","journal-title":"Cancer Treat Rev"},{"key":"3594_CR44","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1158\/1078-0432.CCR-23-3588","volume":"30","author":"ER Balasooriya","year":"2024","unstructured":"Balasooriya ER, Wu Q, Ellis H, Zhen Y, Norden BL, Corcoran RB, et al. The irreversible FGFR inhibitor KIN-3248 overcomes FGFR2 kinase domain mutations. Clin Cancer Res. 2024;30:2181\u201392.","journal-title":"Clin Cancer Res"},{"key":"3594_CR45","doi-asserted-by":"publisher","first-page":"14861","DOI":"10.1074\/jbc.M109.099879","volume":"285","author":"T Yuan","year":"2010","unstructured":"Yuan T, Wang Y, Zhao ZJ, Gu H. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J Biol Chem. 2010;285:14861\u201370.","journal-title":"J Biol Chem"},{"key":"3594_CR46","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1186\/bcr3134","volume":"14","author":"F Su","year":"2012","unstructured":"Su F, Ren F, Rong Y, Wang Y, Geng Y, Wang Y, Feng M, et al. Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res. 2012;14:R38.","journal-title":"Breast Cancer Res"},{"key":"3594_CR47","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cac2.12632","volume":"45","author":"A Azad","year":"2025","unstructured":"Azad A, Arshad M, Generali D, Feldinger K, Gijsen M, Strina C, et al. PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer. Cancer Commun. 2025;45:68\u201373.","journal-title":"Cancer Commun"},{"key":"3594_CR48","doi-asserted-by":"publisher","first-page":"C548","DOI":"10.1152\/ajpcell.00415.2011","volume":"303","author":"Q Hao","year":"2012","unstructured":"Hao Q, Samten B, Ji HL, Zhao ZJ, Tang H. Tyrosine phosphatase PTP-MEG2 negatively regulates vascular endothelial growth factor receptor signaling and function in endothelial cells. Am J Physiol Cell Physiol. 2012;303:C548\u2013553.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3594_CR49","doi-asserted-by":"publisher","first-page":"e74670","DOI":"10.1371\/journal.pone.0074670","volume":"8","author":"R Li","year":"2013","unstructured":"Li R, You S, Hu Z, Chen ZG, Sica GL, Khuri FR, et al. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PLoS One. 2013;8:e74670.","journal-title":"PLoS One"},{"key":"3594_CR50","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1158\/1078-0432.CCR-15-2218","volume":"22","author":"VM Macaulay","year":"2016","unstructured":"Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, et al. Phase I dose-escalation study of Linsitinib (OSI-906) and erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2016;22:2897\u2013907.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03594-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03594-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T03:04:26Z","timestamp":1767063866000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-025-03594-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3594"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03594-2","relation":{},"ISSN":["1756-9966"],"issn-type":[{"type":"electronic","value":"1756-9966"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"10 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Committee of Qilu Hospital of Shandong University. This study was conducted in accordance with the principles of the Declaration of Helsinki and Istanbul.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"332"}}